A share price of Mersana Therapeutics Inc [MRSN] is currently trading at $0.65, up 7.26%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRSN shares have gain 17.75% over the last week, with a monthly amount drifted -60.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, JP Morgan upgraded its rating to Neutral on March 19, 2024, and kept the price target unchanged to $5. On February 29, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $7 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $7 on February 29, 2024. BTIG Research upgraded its rating to a Buy but $6 remained the price target by the analyst firm on February 29, 2024. Citigroup upgraded its rating to Buy for this stock on December 04, 2023, and upped its price target to $5. In a note dated July 28, 2023, Robert W. Baird downgraded an Neutral rating on this stock and revised its target price from $7 to $1.
Mersana Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.49 and $6.28. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $0.65 at the most recent close of the market. An investor can expect a potential return of 361.54% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
Trailing Twelve Months sales for Mersana Therapeutics Inc [NASDAQ:MRSN] were 34.84M which represents 63.65% growth. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -2.28%, Pretax Profit Margin comes in at -2.13%, and Net Profit Margin reading is -2.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -4.01 and Total Capital is -0.78. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of30.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5920 points at the first support level, and at 0.5365 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6782, and for the 2nd resistance point, it is at 0.7089.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mersana Therapeutics Inc [NASDAQ:MRSN] is 2.35. As well, the Quick Ratio is 2.35, while the Cash Ratio is 1.15. Considering the valuation of this stock, the price to sales ratio is 2.30, the price to book ratio is 75.82.
Transactions by insiders
Recent insider trading involved Mandelia Ashish, VP, Chief Accounting Officer, that happened on Jan 16 ’25 when 3554.0 shares were sold. Director, Protopapas Anna completed a deal on Jan 16 ’25 to sell 8637.0 shares. Meanwhile, SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold 8048.0 shares on Jan 16 ’25.
